New brand identity roll-out signals the full integration of recently acquired businesses Penn Pharma and Biotec Services International
Pharmaceutical services provider PCI unveiled its new brand identity at CPhI Worldwide 2015, signalling the full integration of recently acquired businesses Penn Pharma and Biotec Services International, additions that significantly expand PCI’s broad drug development services.
With headquarters in Philadelphia, PA, PCI’s global reach is balanced with local focus through its operations in North America and Europe, supporting medicines destined for more than 100 countries around the world. All parts of the PCI organization will now operate under the PCI Pharma Services name and brand.
Bill Mitchell, PCI´s President and Chief Executive, said: 'We strive to position PCI to best support our clients in bringing new medicines to successful commercialisation. Our continued investments expand the broad service offerings we can provide clients as they enter clinical study, progress towards commercial launch, and ultimately aid in their market competitiveness throughout the product’s lifecycle. The new brand is reflective of the expanded scope of services and the partnership we enjoy with our clients.'
The combined PCI business delivers full service ‘molecule to market’ pharmaceutical expertise to customers in the global healthcare industry, taking compounds from the earliest stages of development through to successful launch and ongoing supply. Working as a trusted partner to pharmaceutical and biotech companies, PCI ensures speed to market and commercial success for its customers across the world by virtue of expert services including: drug development, analytical services, clinical trial supply including drug manufacture, packaging and labeling, as well as global storage and distribution services, and commercial services including manufacturing, packaging, and serialisation.
Mitchell added: 'Since its creation in 2013, PCI has focused on strategic investments and acquisitions with a strategy to best support our client needs with a model of industry-leading expertise, world-class facilities, and cutting edge technologies. This unique blend enables us to address evolving global drug development needs at each stage of the product lifecycle.'
PCI features cGMP manufacturing, laboratory, packaging, storage and distribution facilities across the two continents audited by both the MHRA and FDA, as well as major regulatory bodies in Europe, North America, South America and the Asia Pacific region. With an exemplary regulatory record and export experience, PCI’s 3,000 highly trained associates serve as trusted partners to its customers, dedicated to ensuring outstanding quality and care throughout all stages of the relationship.
Mitchell added: 'Our growth over the past three years reflects our commitment to bring together the expertise and experience of world-class pharmaceutical organisations. In doing so, we have significantly expanded our capability to deliver a broader range of services for both our current and our future customers, in North America and Europe as well as emerging markets.'